Heparin therapy: Current regimens and principles of monitoring

Postgraduate Medicine

Volumn 99, Issue 6, 1996, Pages 64-76

  Berry, Brian R ^a   Nantel, Stephen ^b  

^a ROYAL JUBILEE HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ANTICOAGULATION; ARTERY THROMBOSIS; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; DISEASE CONTROL; HEART INFARCTION; HEMODIALYSIS; HEPARINIZATION; HUMAN; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PATIENT MONITORING; TREATMENT PLANNING; VEIN THROMBOSIS;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0029893344     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.1080/00325481.1996.11946137     Document Type: Article

References (19)

1. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation 1994;89(3):1449-68
2. Leclerc JR. Mechanisms of action of UFH and LMWH. In: Leclerc JR, ed. Venous thromboembolic disorders. Philadelphia: Lea & Febiger, 1991:84-101
3. Jordan RE, Oosta GM, Gardner WT, et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980;255(21):10081-90
4. Clagett GP, Anderson FA Jr, Heit J, et al. Prevention of venous thromboembolism. Chest 1995;108(4 Suppl):312-34S
5. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995;108(4 Suppl):305-11S
6. Cairns JA, Lewis HD Jr, Meade TW, et al. Antithrombotic agents in coronary artery disease. Chest 1995;108(4 Suppl):380-400S
7. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized controlled trial. Ann Intern Med 1993;119(9):874-81
8. Andrew M, Johnston M. An approach to the infant with impaired hemostasis. In: Thomson JM, ed. Blood coagulation and haemostasis: a practical guide. 4th ed. New York: Churchill Livingstone, 1991:209-60
9. Kitchen S, Preston FE. The ISI/INR system is an inappropriate model for heparin dosage monitoring using the APTT. Br J Haematol 1995;89(Suppl 1):50
10. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119(2):104-9
11. Krulder JW, Van den Besselaar AM, Van der Meer FJ, et al. Diurnal changes in heparin effect during continuous constant-rate infusion: a study in nine patients with venous thromboembolism. J Intern Med 1994;235(5):411-7
12. 2 pp 17-36
13. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(4 Suppl):258-75S
14. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(4 Suppl):276-90S
15. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152(8):1589-95
16. Warkentin TE, Kelton JG. Heparin and platelets. Hematol Oncol Clin North Am 1990;4(1):243-64
17. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69(4):344-50
18. Stewart MW, Etches WS, Boshkov LK, et al. Heparin-induced thrombocytopenia: an improved method of detection based on lumiaggregometry. Br J Haematol 1995;91(1):173-7
19. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90(1):1-7